Income Statement
Revenue$8.6B
Gross Profit$5.9B
Operating Income$2.7B
EBITDA$3.9B
Net Income$1.8B
AMGN
Amgen Inc.
NMSSector: HealthcareIndustry: Drug Manufacturers - General
Valuation
Market Cap
$190.42B
Enterprise Value
$235.70B
P/E
24.6
TTMFwd P/E
15.0
1YP/B
20.7
P/S
5.1
TTMPEG
2.32
EV/EBITDA
13.9
EV/Revenue
6.3
FCF Yield
4.1%
EPS (TTM)
$14.36
Fwd EPS
$23.48
Book Value
$17.03
Market Data
Beta
0.42
Avg Volume
2.8M
Shares Out
539.7M
Float
538.2M
Short % Float
2.2%
Insider %
0.2%
Institutional %
85.2%
D/E
623.8
Current Ratio
1.3
ROE
101.3%
ROA
8.3%
Rev Growth
5.8%
Net Inc Growth
4.4%
Profit Margin
21.0%
Op Margin
33.8%
Gross Margin
71.4%
Total Cash
$12.04B
Total Debt
$57.32B
Financials
Latest period financial summary
Balance Sheet
Total Assets$92.5B
Current Assets$31.5B
Cash$12.0B
Total Liabilities$83.3B
Equity$9.2B
Total Debt$57.3B
Cash Flow
Operating CF$2.2B
Investing CF$-716.0M
Financing CF$1.4B
Free Cash Flow$1.5B
Financial Trends
Revenue$8.6B
2022/122026/3
Net Income$1.8B
2022/122026/3
EBITDA$3.9B
2022/122026/3
Free Cash Flow$1.5B
2022/122026/3
Period Analysis
Margins & Ratios
| Metric | 2022/12 | 2023/12 | 2024/9 | 2024/12 | 2025/3 | 2025/6 | 2025/9 | 2025/12 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.3B | $28.2B | — | $33.4B | $8.1B | $9.2B | $9.6B | $36.8B |
| Gross Margin | +75.7% | +70.0% | — | +61.5% | +63.6% | +67.2% | +67.8% | +67.2% |
| EBITDA Margin | +46.2% | +52.5% | — | +40.0% | +50.1% | +39.3% | +61.9% | +46.0% |
| Operating Margin | +36.3% | +28.0% | — | +21.7% | +14.5% | +28.9% | +26.4% | +24.7% |
| Net Margin | +24.9% | +23.8% | — | +12.2% | +21.2% | +15.6% | +33.7% | +21.0% |
| Current Ratio | 1.41 | 1.65 | — | 1.26 | 1.17 | 1.31 | 1.28 | 1.14 |
| Debt / Equity | 10.64 | 10.37 | — | 10.23 | 9.24 | 7.57 | 5.67 | 6.31 |
| Net Debt / EBITDA | 2.57 | 3.63 | — | 3.60 | 11.90 | 13.37 | 7.63 | 2.69 |
| ROE | +179.0% | +107.8% | — | +69.6% | +27.9% | +19.3% | +33.4% | +89.1% |
| ROA | +10.1% | +6.9% | — | +4.5% | +1.9% | +1.6% | +3.6% | +8.5% |
| Leverage | 0.94 | 0.94 | — | 0.94 | 0.93 | 0.92 | 0.89 | 0.90 |
Company Profile
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Employees
32K
Location
Thousand Oaks, CA
Country
US
Golden Bazaar VerifiedUpdated: Jun 26, 2026Data Source: Golden Bazaar Verified · Updated: Jun 26, 2026
Sector Peers
Comparison Screen →Healthcare
Compare with similar companies in the same sector.
This page is prepared by Golden Bazaar using publicly available data. Not investment advice.